You are here

Article Text

Article menu
Download PDFPDF
Clinical science
Long-term outcome of treat and extend intravitreal ziv-aflibercept therapy
  1. Ahmad M Mansour1,2,
  2. Abdulrazzak Charbaji3,4,
  3. Michel Eid Farah5,
  4. Hana A Mansour1,
  5. Jay Chhablani6
  1. 1 Department of Ophthalmology, American University of Beirut, Beirut, Lebanon
  2. 2 Department of Ophthalmology, Rafic Hariri University Hospital, Beirut, Lebanon
  3. 3 Department of Statistics and Research Methodology, Lebanese American University, Beirut, Lebanon
  4. 4 Department of Statistics and Research Methodology, Lebanese University, Beirut, Lebanon
  5. 5 Department of Ophthalmology, Federal University of São Paulo, São Paulo, Brazil
  6. 6 Smt Kanuri Santhamma Centre for Vitreoretinal Diseases, LV Prasad Eye Institute, Hyderabad, India
  1. Correspondence to Dr Jay Chhablani, Smt Kanuri Santhamma Centre for Vitreoretinal Diseases, LV Prasad Eye Institute, Hyderabad, Andhra Pradesh, India; jay.chhablani{at}gmail.com

Abstract

Aim To assess the 30-month outcome of treat and extend (TAE) intravitreal ziv-aflibercept therapy in eyes with macular diseases.

Methods In this prospective study, consecutive subjects received intravitreal 0.05 mL ziv-aflibercept (1.25 mg) injections for various macular diseases. Outcome measures were best-corrected visual acuity (BCVA) (logarithm of the minimum angle of resolution) and central macular thickness (CMT) on spectral domain optical coherence tomography. Paired comparison was done using Wilcoxon signed-rank test calculator.

Results Fifty-three eyes of 48 subjects (33 naïve eyes) received intravitreal ziv-aflibercept and were followed between 12 and 30 months following TAE included neovascular age-related macular degeneration (nAMD) (35 eyes) and diabetic macular oedema (DMO) (18 eyes). In eyes with nAMD, CMT decreased by 107.8 µm at the 30-month follow-up (p=0.012) with BCVA gain of 0.52 (p=0.001). In eyes with DMO, CMT decreased by 224.3 µm at the 30-month follow-up (p=0.027) with BCVA gain of 0.46 (p=0.042). Combining all disease categories, the mean number of injections was 9.2 at month 12, 2.5 between 12 and 18 months, 1.6 between 18 and 24 months and 1.0 between 24 and 30 months.

Conclusions Using TAE regimen, intravitreal ziv-aflibercept appeared efficacious at managing retinal disease through month 30 using the TAE regimen.

  • Macula
  • Retina
  • Treatment other

https://doi.org/10.1136/bjophthalmol-2018-312593

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors AMM, MEF and JC: design; AMM: conduct of the study; AMM: collection; AMM: management; AMM, MEF, JC and AC: analysis; AC: interpretation of the data; AMM, JC and MEF: preparation; AMM, MEFA and JC: review; AMM, MEF, JC and AC: approval of the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient consent Obtained.

    • Ethics approval Rafic Hariri University Hospital.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    Linked Articles

    • At a glance
      Highlights from this issue
      Keith Barton James Chodosh Jost B Jonas
      British Journal of Ophthalmology 2019; 103 i-ii Published Online First: 21 Jun 2019. doi: 10.1136/bjophthalmol-2019-314702